Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity.

Rivera LB, Brekken RA.

J Cell Biol. 2011 Jun 27;193(7):1305-19. doi: 10.1083/jcb.201011143.

2.

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC.

Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152.

3.

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC.

Science. 2011 Apr 15;332(6027):358-61. doi: 10.1126/science.1192149.

4.

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK.

Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14. doi: 10.1073/pnas.1018892108. Epub 2011 Jan 31.

5.

Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.

An J, Nakajima T, Kuba K, Kimura A.

Hypertens Res. 2010 Aug;33(8):831-5. doi: 10.1038/hr.2010.79. Epub 2010 May 27.

PMID:
20505677
6.

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.

Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.

Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.

7.

Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD, Brekken RA.

Dis Model Mech. 2010 Jan-Feb;3(1-2):57-72. doi: 10.1242/dmm.003228. Epub 2009 Dec 9.

8.

Role of transforming growth factor beta in cancer microenvironment.

de la Cruz-Merino L, Henao-Carrasco F, García-Manrique T, Fernández-Salguero PM, Codes-Manuel de Villena M.

Clin Transl Oncol. 2009 Nov;11(11):715-20. Review.

PMID:
19917534
9.

Transforming growth factor-beta: a target for cancer therapy.

Kelly RJ, Morris JC.

J Immunotoxicol. 2010 Mar;7(1):15-26. doi: 10.3109/15476910903389920. Review.

PMID:
19916703
10.

The Yin and Yang of CD4(+) regulatory T cells in autoimmunity and cancer.

Galgani M, Di Giacomo A, Matarese G, La Cava A.

Curr Med Chem. 2009;16(35):4626-31. Review.

PMID:
19903146
11.

Mechanisms of the epithelial-mesenchymal transition by TGF-beta.

Wendt MK, Allington TM, Schiemann WP.

Future Oncol. 2009 Oct;5(8):1145-68. doi: 10.2217/fon.09.90. Review.

12.

Regulatory T cells and immune tolerance to tumors.

Cao X.

Immunol Res. 2010 Mar;46(1-3):79-93. doi: 10.1007/s12026-009-8124-7. Review.

PMID:
19763889
13.

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.

Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G.

Hepatology. 2009 Oct;50(4):1140-51. doi: 10.1002/hep.23118.

PMID:
19711426
14.

Circulating transforming growth factor-beta in Marfan syndrome.

Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC; GenTAC Consortium.

Circulation. 2009 Aug 11;120(6):526-32. doi: 10.1161/CIRCULATIONAHA.108.841981. Epub 2009 Jul 27.

15.

Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.

Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H.

Oncol Rep. 2009 Aug;22(2):355-60.

PMID:
19578777
16.

Regulatory T cells: major players in the tumor microenvironment.

Beyer M, Schultze JL.

Curr Pharm Des. 2009;15(16):1879-92. Review.

PMID:
19519430
17.

Transforming growth factor-beta signaling and tumor angiogenesis.

Pardali E, ten Dijke P.

Front Biosci (Landmark Ed). 2009 Jun 1;14:4848-61. Review.

PMID:
19482591
18.

Myeloid-derived suppressor cells: linking inflammation and cancer.

Ostrand-Rosenberg S, Sinha P.

J Immunol. 2009 Apr 15;182(8):4499-506. doi: 10.4049/jimmunol.0802740. Review.

19.

Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.

Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunother. 2009 Jan;32(1):12-21. doi: 10.1097/CJI.0b013e318189f13c.

20.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.

Supplemental Content

Support Center